Kaydence Pharma – Successful completion of Pre-IND meeting with FDA
Oslo, Norway (15 January 2019) — Kaydence Pharma AS, the development stage pharmaceutical company spun-out of NattoPharma in 2017, reports today that it has successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA). At the meeting, the FDA addressed questions regarding key components of the planned IND application and the clinical/regulatory pathway for MQ7, Kaydence Pharma’s novel drug candidate for the treatment of arterial stiffness in stable renal transplant recipients with subclinical vitamin K deficiency.
“The continued positive momentum in the Kaydence Pharma development plan is very encouraging and validates the strategic decision to spin the activity out of NattoPharma’s ordinary supplement business in 2017. This decision ensures that Kaydence continues to have both the correct focus and attention from competent people to succeed. NattoPharma is very enthusiastic about this project and has great faith in the future potential for a pharmaceutical drug based on the extensive clinical understanding that NattoPharma has developed over the last 10 years of working with MK-7." said Kjetil Ramsøy, CEO of NattoPharma.
The press release issued by Kaydence Pharma is attached to this announcement for further reading.
X X X
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7 and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company has a North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
For more information, please contact:
Kjetil Ramsøy, NattoPharma Chief Executive Officer